Related Experiment Video
Updated: Mar 11, 2026
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer
Yayi He1, Paul A Bunn2, Caicun Zhou1
1Department of Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, People's Republic of China.
Background:
Nature killer (NK) cells are the immune system's first line of defense against both viral infections and tumors. Killer cell immunoglobulin-like receptors (KIRs) are associated with susceptibility to different types of cancers. We investigated KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression and their association with survival in non-small cell lung cancer (NSCLC).
Methods:
The expression of KIR 2D (L1, L3, L4, S4) (BC032422/ ADQ31987/ NP_002246/ NP_036446, ABCAM) and KIR 3DL1 (AA 1-444, ABCAM) protein was assessed by immunohistochemistry (IHC) in 62 NSCLC patients.
Results:
KIR 2D (L1, L3, L4, S4) and KIR 3DL1 were expressed both on NSCLC tumor cells and tumor infiltrating lymphocytes (TILs). Fourteen samples (22.6%) stained positive for KIR 2D (L1, L3, L4, S4) on the tumor cells, and 10 (16.1%) had positive expression on the TILs. Thirty-three samples (53.2%) stained positive for KIR 3DL1 on the tumor cells, and 31 (50.0%) had positive expression on the TILs. Patients with negative KIR 2D (L1, L3, L4, S4) expression on tumor cells or TILs had longer overall survival (OS) than patients who are KIR 2D (L1, L3, L4, S4) positive on tumor cells (40.70 weeks, 95% CI 24.76-56.65 vs. 7.10 weeks, 95% CI 0.00-19.38, P = 0.014) or TILs (40.70 weeks, 95% CI 24.05-57.35 vs. 3.90 weeks, 95% CI 0.00-9.17, P < 0.001). Likewise, longer OS was significantly correlated with negative expression of KIR 3DL1 on tumor cells (62.30 weeks, 95% CI 0.00-177.37 vs. 13.10 weeks, 95% CI 3.42-22.78, P < 0.001) or TILs (62.30 weeks, 95% CI 0.00-152.05 vs. 12.10 weeks, 95% CI 2.61-21.59, P < 0.001). Cox regression analysis showed that KIR 2D (L1, L3, L4, S4) on TILs was correlated with OS (P = 0.032, Odds Ratio 2.628 95%CI 1.089-6.340).
Conclusions:
KIR 2D (L1, L3, L4, S4) and KIR 3DL1 expression was correlated with poor prognosis in NSCLC patients.
Insights
Killer cell immunoglobulin-like receptors (KIRs) like KIR 2D and KIR 3DL1 are linked to poor outcomes in non-small cell lung cancer (NSCLC). Negative expression of these KIRs on tumor cells or tumor-infiltrating lymphocytes (TILs) correlated with longer patient survival.
Area of Science:
- Immunology
- Oncology
Background:
- Nature killer (NK) cells are crucial for immune defense against infections and tumors.
- Killer cell immunoglobulin-like receptors (KIRs) are implicated in cancer susceptibility.
- This study focuses on KIR 2D (L1, L3, L4, S4) and KIR 3DL1 in non-small cell lung cancer (NSCLC).
Purpose of the Study:
- To investigate the expression of KIR 2D (L1, L3, L4, S4) and KIR 3DL1 proteins in NSCLC.
- To determine the association between KIR expression and patient survival in NSCLC.
Main Methods:
- Immunohistochemistry (IHC) was used to assess KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression.
- The study included 62 patients diagnosed with NSCLC.
- Expression was evaluated on both tumor cells and tumor-infiltrating lymphocytes (TILs).
Main Results:
- KIR 2D (L1, L3, L4, S4) and KIR 3DL1 proteins were expressed on NSCLC tumor cells and TILs.
- Negative expression of KIR 2D (L1, L3, L4, S4) on tumor cells or TILs was associated with significantly longer overall survival (OS).
- Similarly, negative KIR 3DL1 expression on tumor cells or TILs correlated with extended OS.
- Cox regression indicated KIR 2D (L1, L3, L4, S4) on TILs was linked to OS (P=0.032).
Conclusions:
- KIR 2D (L1, L3, L4, S4) and KIR 3DL1 expression is associated with a poor prognosis in NSCLC patients.
- The presence of these KIRs may indicate a worse outcome for individuals with non-small cell lung cancer.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
